Kodiak Sciences Shares Surge Ahead of Phase 3 Readout
Dow Jones
Sep 26
Shares of Kodiak Sciences surged ahead of the company's planned readout of topline results from a Phase 3 study of an eye disease treatment.
The stock was up 17% to $38 in after-hours trading on Friday. Shares closed down 2.6% at $32.35, and are up 16% year-to-date.
The biotechnology company said Friday that it plans to report results from the study evaluating both Zenkuda, or tarcocimab tedromer, and KSI-501, or tabirafusp alfa tedromer, to treat wet age-related macular degeneration.
The readout is scheduled for 8:30 a.m. ET on Monday.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.